Becton, Dickinson and Company

(New York Stock Exchange)
Back to all articles
Bullish +65

Becton Dickinson: Fiscal Q2 Earnings Snapshot

AI-generated analysis

📈 Becton Dickinson reported fiscal Q2 net income of $277 million, or 94 cents per share.

📊 Adjusted earnings for non-recurring costs were $3.19 per share, beating the $3.04 analyst average.

💰 Revenue reached $4.91 billion, surpassing the Street forecast of $4.84 billion.

🔮 The company provides full-year earnings guidance ranging from $12.75 to $12.85 per share.

📉 BDX stock has declined approximately 5% over the last 12 months, underperforming the S&P 500's 11% gain.

🏥 The medical device manufacturer is based in Franklin Lakes, New Jersey.

Bullish Signals
  • BDX reported fiscal Q2 earnings of $3.19 per share (adjusted), which exceeded the average analyst estimate of $3.04 per share.
  • Revenue of $4.91 billion surpassed the consensus forecast of $4.84 billion, indicating strong top-line growth.
  • The company provided a full-year earnings guidance range of $12.75 to $12.85 per share, suggesting continued profitability.
Risk Factors
  • BDX shares have dropped roughly 5% over the last 12 months while the S&P 500 index has increased 11%, indicating relative underperformance.
  • The stock has declined slightly since the beginning of the year despite reporting earnings that beat expectations.
Full Analysis
Becton Dickinson and Co. (BDX) reported fiscal second-quarter results that surpassed Wall Street expectations, driven by strong performance in its medical device manufacturing sector. The company posted a net profit of $277 million, translating to 94 cents per share on a GAAP basis. When adjusted for non-recurring costs, earnings reached $3.19 per share, significantly beating the average analyst estimate of $3.04 per share provided by Zacks Investment Research. Revenue for the quarter totaled $4.91 billion, also exceeding the consensus forecast of $4.84 billion from seven surveyed analysts. This financial strength supports the company's full-year earnings guidance, which projects a range between $12.75 and $12.85 per share. Despite these solid operational results, BDX shares have underperformed the broader market, dropping roughly 5% over the last 12 months while the S&P 500 index has gained 11% since the beginning of the year.